176 related articles for article (PubMed ID: 37040900)
1. High mesothelin expression by immunohistochemistry predicts improved survival in pleural mesothelioma.
Chu GJ; Linton A; Kao S; Klebe S; Adelstein S; Yeo D; Rasko JEJ; Cooper WA
Histopathology; 2023 Aug; 83(2):202-210. PubMed ID: 37040900
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
[TBL] [Abstract][Full Text] [Related]
3. One Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy.
Hager T; Borchert S; Wessolly M; Mathilakathu A; Mairinger E; Kollmeier J; Mairinger T; Hegedus B; Greimelmaier K; Wohlschlaeger J; Herrmann K; Mairinger FD
Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047331
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients.
Servais EL; Colovos C; Rodriguez L; Bograd AJ; Nitadori J; Sima C; Rusch VW; Sadelain M; Adusumilli PS
Clin Cancer Res; 2012 May; 18(9):2478-89. PubMed ID: 22371455
[TBL] [Abstract][Full Text] [Related]
5. MSLN gene silencing has an anti-malignant effect on cell lines overexpressing mesothelin deriving from malignant pleural mesothelioma.
Melaiu O; Stebbing J; Lombardo Y; Bracci E; Uehara N; Bonotti A; Cristaudo A; Foddis R; Mutti L; Barale R; Gemignani F; Giamas G; Landi S
PLoS One; 2014; 9(1):e85935. PubMed ID: 24465798
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin antigen density influences anti-mesothelin chimeric antigen receptor T cell cytotoxicity.
Chu GJ; Bailey CG; Nagarajah R; Liang O; Metierre C; Sagnella SM; Castelletti L; Yeo D; Adelstein S; Rasko JEJ
Cytotherapy; 2024 Apr; 26(4):325-333. PubMed ID: 38349311
[TBL] [Abstract][Full Text] [Related]
7. Nuclear grading, BAP1, mesothelin and PD-L1 expression in malignant pleural mesothelioma: prognostic implications.
Forest F; Patoir A; Dal Col P; Sulaiman A; Camy F; Laville D; Bayle-Bleuez S; Fournel P; Habougit C
Pathology; 2018 Oct; 50(6):635-641. PubMed ID: 30145072
[TBL] [Abstract][Full Text] [Related]
8. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells.
He X; Wang L; Riedel H; Wang K; Yang Y; Dinu CZ; Rojanasakul Y
Mol Cancer; 2017 Mar; 16(1):63. PubMed ID: 28288645
[TBL] [Abstract][Full Text] [Related]
9. Mesothelin (MSLN) promoter is hypomethylated in malignant mesothelioma, but its expression is not associated with methylation status of the promoter.
Tan K; Kajino K; Momose S; Masaoka A; Sasahara K; Shiomi K; Izumi H; Abe M; Ohtsuji N; Wang T; Hino O; Fujii H
Hum Pathol; 2010 Sep; 41(9):1330-8. PubMed ID: 20573372
[TBL] [Abstract][Full Text] [Related]
10. Prognosis of patients with malignant mesothelioma by expression of programmed cell death 1 ligand 1 and mesothelin in a contemporary cohort in Finland.
Vizcaya D; Farahmand B; Walter AO; Kneip C; Jöhrens K; Tukiainen M; Schmitz AA
Cancer Treat Res Commun; 2020; 25():100260. PubMed ID: 33310366
[TBL] [Abstract][Full Text] [Related]
11. Immuno-modulators enhance antigen-specific immunity and anti-tumor effects of mesothelin-specific chimeric DNA vaccine through promoting DC maturation.
Chen YL; Chang MC; Chiang YC; Lin HW; Sun NY; Chen CA; Sun WZ; Cheng WF
Cancer Lett; 2018 Jul; 425():152-163. PubMed ID: 29596890
[TBL] [Abstract][Full Text] [Related]
12. Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1.
Eguchi T; Kadota K; Mayor M; Zauderer MG; Rimner A; Rusch VW; Travis WD; Sadelain M; Adusumilli PS
Oncotarget; 2017 Sep; 8(44):77872-77882. PubMed ID: 29100432
[TBL] [Abstract][Full Text] [Related]
13. Dominant-negative transforming growth factor-β receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer.
Li K; Xu J; Wang J; Lu C; Dai Y; Dai Q; Zhang W; Xu C; Wu S; Kang Y
Cancer Immunol Immunother; 2023 Apr; 72(4):917-928. PubMed ID: 36166071
[TBL] [Abstract][Full Text] [Related]
14. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope.
Liu XF; Onda M; Schlomer J; Bassel L; Kozlov S; Tai CH; Zhou Q; Liu W; Tsao HE; Hassan R; Ho M; Pastan I
Proc Natl Acad Sci U S A; 2024 Jan; 121(4):e2317283121. PubMed ID: 38227666
[TBL] [Abstract][Full Text] [Related]
15. Mesothelin-targeted CAR-T cell therapy for solid tumors.
Klampatsa A; Dimou V; Albelda SM
Expert Opin Biol Ther; 2021 Apr; 21(4):473-486. PubMed ID: 33176519
[No Abstract] [Full Text] [Related]
16. Overexpression of Mesothelin in Pancreatic Ductal Adenocarcinoma (PDAC).
Le K; Wang J; Zhang T; Guo Y; Chang H; Wang S; Zhu B
Int J Med Sci; 2020; 17(4):422-427. PubMed ID: 32174772
[No Abstract] [Full Text] [Related]
17. Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.
Jafarzadeh L; Masoumi E; Alishah K; Mirzaei HR; Jamali A; Fallah-Mehrjardi K; Rostamian H; Khakpoor-Koosheh M; Meshkani R; Noorbakhsh F; Hadjati J
Iran J Allergy Asthma Immunol; 2020 Jun; 19(3):264-275. PubMed ID: 32615660
[TBL] [Abstract][Full Text] [Related]
18. Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer.
Lv J; Zhao R; Wu D; Zheng D; Wu Z; Shi J; Wei X; Wu Q; Long Y; Lin S; Wang S; Wang Z; Li Y; Chen Y; He Q; Chen S; Yao H; Liu Z; Tang Z; Yao Y; Pei D; Liu P; Zhang X; Zhang Z; Cui S; Chen R; Li P
J Hematol Oncol; 2019 Feb; 12(1):18. PubMed ID: 30777106
[TBL] [Abstract][Full Text] [Related]
19. Mesothelin expression remodeled the immune-matrix tumor microenvironment predicting the risk of death in patients with malignant pleural mesothelioma.
Qualiotto AN; Baldavira CM; Balancin M; Ab'Saber A; Takagaki T; Capelozzi VL
Front Immunol; 2023; 14():1268927. PubMed ID: 37901248
[TBL] [Abstract][Full Text] [Related]
20. Mesothelin-targeted CAR-T therapy combined with irinotecan for the treatment of solid cancer.
Zhu Y; Zuo D; Wang K; Lan S; He H; Chen L; Chen X; Feng M
J Cancer Res Clin Oncol; 2023 Nov; 149(16):15027-15038. PubMed ID: 37612388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
